Prolia® (denosumab) Arriving Worldwide for the treatment of postmenopausal osteoporosis — ... « denosumab

(Klikkaukset: 283;verkkosivu lisätty: Jul 2, 2015, denosumab)

Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.

prolia denosumab rank ligand rank ligand inhibitor bone loss